Lerisetron

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lerisetron
Lerisetron.svg
Clinical data
ATC code
  • None
Identifiers
Synonyms F-0930-RS
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C18H20N4
Molar mass 292.378 g/mol
 NYesY (what is this?)  (verify)

Lerisetron (code name F-0930-RS) is a drug which acts as an antagonist at the 5-HT3 receptor.[1] It is a potent antiemetic[2][3] and was in clinical trials for the treatment of nausea associated with cancer chemotherapy.[4]

See also[edit]

References[edit]

  1. ^ Orjales, A; Mosquera, R; Labeaga, L; Rodes, R (14 February 1997). "New 2-Piperazinylbenzimidazole Derivatives as 5-HT3 Antagonists. Synthesis and Pharmacological Evaluation". Journal of Medicinal Chemistry. 40 (4): 586–93. PMID 9046349. doi:10.1021/jm960442e. 
  2. ^ Gomez-de-Segura, IA; Grande, AG; De Miguel, E (1998). "Antiemetic Effects of Lerisetron in Radiation-Induced Emesis in the Dog". Acta Oncologica. 37 (7–8): 759–63. PMID 10050999. 
  3. ^ Cooper, M; Sologuren, A; Valiente, R; Smith, J (2002). "Effects of Lerisetron, a New 5-HT3 Receptor Antagonist, on Ipecacuanha-Induced Emesis in Healthy Volunteers". Arzneimittel-Forschung. 52 (9): 689–94. PMID 12404884. doi:10.1055/s-0031-1299952. 
  4. ^ Huckle, R (July 2003). "Lerisetron. FAES". Current Opinion in Investigational Drugs. 4 (7): 874–7. PMID 14619411.